Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
1. Recursion Pharmaceuticals is a leader in TechBio with extensive capabilities. 2. Analyst maintained a Buy rating with a price target of $11. 3. Upcoming May update will provide critical insights and financial guidance. 4. Company forecasts $200 million in near-term milestones and $20 billion in future revenue. 5. RXRX shares declined 4.7% to $7.14 at publication.